GeneraMedix Inc. Announces FDA Approval and Launch of Ampicillin and Sulbactam for Injection, USP
Posted on: Thursday, 9 August 2007, 18:03 CDT
LIBERTY CORNER, N.J., Aug. 9 /PRNewswire/ -- GeneraMedix Inc. has received FDA approval and has launched Ampicillin and Sulbactam for Injection, USP.
GeneraMedix offers Ampicillin and Sulbactam for Injection, USP in 1.5 and 3 gram vials, preservative free.
This is the first product launched resulting from a long term, multi-product development and supply agreement between GeneraMedix Inc. and MN Pharmaceuticals, a leading pharmaceutical manufacturer based in Turkey.
Ronald F. Quadrel, President and CEO of GeneraMedix Inc. stated, "Our long term relationship with MN Pharmaceuticals is another cog in our overall strategy and ongoing commitment to provide our customers with high quality generic injectable products at a competitive price. It is my expectation that this relationship will yield a significant number of products that will help build the GeneraMedix portfolio in the immediate future as well as over the longer term."
M. Levent Selamoglu, CEO of MN Pharmaceuticals said, "This is an exciting and historical moment for MN Pharmaceuticals and the Turkish Pharmaceutical industry. The alliance with GeneraMedix Inc. has opened up the U.S. market to us. I strongly believe that this alliance will bring a new perspective to our company. The history of MN Pharmaceuticals is full of firsts in the Turkish Pharmaceutical Industry and we have added a significant one to that list by achieving this milestone."
About MN Pharmaceuticals
MN Pharmaceuticals is one of the leading and oldest pharmaceutical companies in Turkey. The company is a leading manufacturer of bulk pharmaceutical chemicals and finished dosage forms. MN has state-of the-art, high-capacity injectable and lyophilization facilities. The company received FDA approval of its API and parenteral manufacturing facilities in Istanbul, Turkey in January 2007. Additional information is available on the company's website at http://www.mn.com.tr/
About GeneraMedix Inc.
GeneraMedix Inc. is a privately held pharmaceutical company offering high quality generic injectable products to the U.S. hospital and specialty markets. In addition to its products already marketed, GeneraMedix has a significant number of injectable products under development, as well as a number of products currently under FDA review. Headquartered in Liberty Corner, New Jersey, the company was founded in July of 2004. Additional information is available on the company's website at http://www.generamedix.com/.
GeneraMedix Inc.
CONTACT: Dennis M. Potter, GeneraMedix Inc., +1-908-504-1303 ordpotter@generamedix.com
Web site: http://www.mn.com.tr/http://www.generamedix.com/
Source: PRNewswire
Related Articles
- Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy
- The US Biofuel Industry Especially Ethanol Production Is Expected To Lead The Global Production During The Forecasted Period Of 2008-2017
- Peregrine Pharmaceuticals Highlights Significant Advances in the Company's Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
- Encysive Pharmaceuticals Submits Response to FDA For Thelin New Drug Application
- MySpace Leads in Number of U.S. Video Streams Viewed Online, Capturing 20 Percent Market Share;
- EPIX Pharmaceuticals Files Appeal With FDA Regarding Vasovist(TM) Approvable Letters; Company Remains Committed To Making Novel Blood-Pool Imaging Agent Available in U.S.
- American Pharmaceutical Partners Receives Two FDA Approvals for Ceftriaxone for Injection, USP, Maintaining Company's Leadership Position in the Cephalosporin Market
- American Pharmaceutical Partners Receives Two FDA Approvals for Octreotide Acetate Injection
- Genesis Bioventures Announces Biomedical Diagnostics, Its Breast Cancer Diagnostic Company, Retains a Leading FDA Regulatory Consulting Firm
- Kinpo Makes the Calculation: IBM and Dassault Systemes PLM Solutions Reduce Product Design Time Significantly
 |
 |
User Comments (0)
RSS Feeds